HUE057332T2 - [6R]-MTHF, egy hatásos folátalternatíva 5-fluoruracil-alapú kemoterápiában - Google Patents
[6R]-MTHF, egy hatásos folátalternatíva 5-fluoruracil-alapú kemoterápiábanInfo
- Publication number
- HUE057332T2 HUE057332T2 HUE18150455A HUE18150455A HUE057332T2 HU E057332 T2 HUE057332 T2 HU E057332T2 HU E18150455 A HUE18150455 A HU E18150455A HU E18150455 A HUE18150455 A HU E18150455A HU E057332 T2 HUE057332 T2 HU E057332T2
- Authority
- HU
- Hungary
- Prior art keywords
- mthf
- folate
- fluorouracil
- alternative
- effective
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17187684.0A EP3446704A1 (en) | 2017-08-24 | 2017-08-24 | [6r]-mthf - an efficient folate alternative in 5-fluorouracil based chemotherapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE057332T2 true HUE057332T2 (hu) | 2022-05-28 |
Family
ID=59702573
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE18150455A HUE057332T2 (hu) | 2017-08-24 | 2018-01-05 | [6R]-MTHF, egy hatásos folátalternatíva 5-fluoruracil-alapú kemoterápiában |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US11013744B2 (https=) |
| EP (3) | EP3446704A1 (https=) |
| JP (2) | JP7356411B2 (https=) |
| KR (1) | KR102216031B1 (https=) |
| CN (1) | CN110290802A (https=) |
| AU (1) | AU2018320069B2 (https=) |
| BR (1) | BR112020003585A2 (https=) |
| CA (2) | CA3073555C (https=) |
| DK (1) | DK3446705T3 (https=) |
| ES (1) | ES2901621T3 (https=) |
| HU (1) | HUE057332T2 (https=) |
| IL (1) | IL272874B2 (https=) |
| MX (1) | MX2020002053A (https=) |
| PL (1) | PL3446705T3 (https=) |
| PT (1) | PT3446705T (https=) |
| RU (1) | RU2763934C2 (https=) |
| SG (2) | SG11202001372TA (https=) |
| TW (1) | TWI752147B (https=) |
| WO (1) | WO2019037898A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3446704A1 (en) | 2017-08-24 | 2019-02-27 | Isofol Medical AB | [6r]-mthf - an efficient folate alternative in 5-fluorouracil based chemotherapy |
| US20240350495A1 (en) * | 2023-04-20 | 2024-10-24 | Isofol Medical Ab | [6r]-mthf in b6 enhanced 5-fu based chemotherapy of carcinoma |
| US20240350467A1 (en) * | 2023-04-20 | 2024-10-24 | Isofol Medical Ab | [6r]-mthf in b6 enhanced 5-fu based chemotherapy of pancreatic cancer |
| EP4450071A1 (en) | 2023-04-20 | 2024-10-23 | Isofol Medical AB | [6r]-mthf in b6 enhanced 5-fu based chemotherapy of pancreatic cancer |
| EP4534088A1 (en) | 2023-10-04 | 2025-04-09 | Isofol Medical AB | Arfolitixorin for use in vitamin b6-enhanced, 5-fluorouracil-based chemotherapy of carcinomas |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5376658A (en) | 1990-05-11 | 1994-12-27 | University Of Southern California | 5,10-methylene-tetrahydrofolate as a modulator of a chemotherapeutic agent |
| US7135575B2 (en) | 2003-03-03 | 2006-11-14 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
| KR20070019725A (ko) | 2004-04-02 | 2007-02-15 | 어드벤트륵스 파마슈티칼스, 인크. | 암치료에 사용되는 5,10-메틸렌 테트라하이드로폴레이트의용도 |
| CN1942189A (zh) * | 2004-04-02 | 2007-04-04 | 阿德文特克斯药物有限公司 | 5,10－亚甲基四氢叶酸在癌症治疗中的用途 |
| JP2007531728A (ja) | 2004-04-02 | 2007-11-08 | アドベントルクス ファーマシューティカルズ， インコーポレイテッド | 癌の処置のための５，１０−メチレンテトラヒドロ葉酸の使用 |
| NZ551775A (en) | 2004-06-01 | 2010-12-24 | Univ Virginia | Dual small molecule inhibitors of cancer and angiogenesis |
| EP1968551A2 (en) * | 2005-12-02 | 2008-09-17 | Adventrx Pharmaceuticals, Inc. | Stable pharmaceutical compositions of 5,10 methylenetetrahydrofolate |
| AU2007299080B2 (en) | 2006-09-18 | 2013-04-18 | Boehringer Ingelheim International Gmbh | Method for treating cancer harboring EGFR mutations |
| WO2008109349A1 (en) | 2007-03-06 | 2008-09-12 | Adventrx Pharmaceuticals, Inc. | Improved regimen for treating cancer with 5-fluorouracil, 5,10-methylenetetrahydrofolate and capecitabine |
| WO2008156702A2 (en) | 2007-06-15 | 2008-12-24 | Cequent Pharmaceuticals, Inc. | Bacteria mediated gene silencing |
| AU2008362108B2 (en) | 2008-09-26 | 2015-09-03 | Institut De Cancerologie De L'ouest | Individual 5-fluorouracile dose optimization in FOLFOX treatment |
| JP2013523843A (ja) | 2010-04-15 | 2013-06-17 | ベジェニクス ピーティーワイ リミテッド | Ｖｅｇｆ−ｃ拮抗剤を用いた併用治療 |
| EP2617422A1 (en) | 2012-01-20 | 2013-07-24 | Isofol Medical AB | Anti-tumor activity of reduced folates like methylene-tetrahydrofolate, tetrahydrofolate or methyl-tetrahydrofolate |
| EP2617421A1 (en) * | 2012-01-20 | 2013-07-24 | Isofol Medical AB | Tetrahydrofolates in combination with EGFR-inhibitors in the use of treating cancer |
| EP2837631A1 (en) * | 2013-08-14 | 2015-02-18 | Merck & Cie | New stable salt of 5,10-methylene-(6R)-tetrahydrofolic acid |
| DK3328426T3 (da) | 2015-07-27 | 2021-07-12 | Innocimab Pte Ltd | Behandling af patienter diagnosticeret med pankreatisk duktalt adenocarcinom under anvendelse af monoklonale antistoffer mod den epidermale vækstfaktorreceptor (egfr) |
| EP3305318A1 (en) | 2016-10-05 | 2018-04-11 | Isofol Medical AB | [6r]-5,10-methylenetetrahydrofolate in 5-fluorouracil based chemotherapy |
| EP3446704A1 (en) | 2017-08-24 | 2019-02-27 | Isofol Medical AB | [6r]-mthf - an efficient folate alternative in 5-fluorouracil based chemotherapy |
| EP3446703A1 (en) | 2017-08-24 | 2019-02-27 | Isofol Medical AB | 6r]-mthf multiple bolus administration in 5-fluorouracil based chemotherapy |
| US10292984B2 (en) | 2017-02-14 | 2019-05-21 | Isofol Medical Ab | Methods for increasing blood plasma 2′-deoxyuridine (dUrd) and thymidylate synthase inhibition |
| US20230116137A1 (en) * | 2017-08-24 | 2023-04-13 | Isofol Medical Ab | Methods for treating colorectal and metastatic colorectal cancers |
| JP7258759B2 (ja) | 2018-01-05 | 2023-04-17 | アイソフォル・メディカル・エービー | 大腸癌及び転移性大腸癌を治療する方法 |
| WO2019229115A1 (en) | 2018-05-30 | 2019-12-05 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for treating cancer |
| WO2023046304A1 (en) | 2021-09-27 | 2023-03-30 | Isofol Medical Ab | [6r]-mthf in 5-fu based chemotherapy of braf- or kras-mutated colorectal cancer |
| WO2023046305A1 (en) * | 2021-09-27 | 2023-03-30 | Isofol Medical Ab | [6r]-mthf in 5-fu based chemotherapy of left-sided colorectal cancer |
| WO2023046307A1 (en) | 2021-09-27 | 2023-03-30 | Isofol Medical Ab | [6r]-mthf in 5-fu based chemotherapy of right-sided colorectal cancer |
| US20230095428A1 (en) * | 2021-09-28 | 2023-03-30 | Isofol Medical Ab | [6r]-mthf in 5-fu based chemotherapy of braf- or kras-mutated colorectal cancer |
| US20230097085A1 (en) | 2021-09-28 | 2023-03-30 | Isofol Medical Ab | [6r]-mthf in 5-fu based chemotherapy of right-sided colorectal cancer |
| US20240350495A1 (en) | 2023-04-20 | 2024-10-24 | Isofol Medical Ab | [6r]-mthf in b6 enhanced 5-fu based chemotherapy of carcinoma |
| US20240350467A1 (en) | 2023-04-20 | 2024-10-24 | Isofol Medical Ab | [6r]-mthf in b6 enhanced 5-fu based chemotherapy of pancreatic cancer |
-
2017
- 2017-08-24 EP EP17187684.0A patent/EP3446704A1/en not_active Withdrawn
-
2018
- 2018-01-05 PL PL18150455T patent/PL3446705T3/pl unknown
- 2018-01-05 SG SG11202001372TA patent/SG11202001372TA/en unknown
- 2018-01-05 DK DK18150455.6T patent/DK3446705T3/da active
- 2018-01-05 BR BR112020003585-8A patent/BR112020003585A2/pt not_active IP Right Cessation
- 2018-01-05 PT PT181504556T patent/PT3446705T/pt unknown
- 2018-01-05 IL IL272874A patent/IL272874B2/en unknown
- 2018-01-05 JP JP2020510518A patent/JP7356411B2/ja active Active
- 2018-01-05 AU AU2018320069A patent/AU2018320069B2/en active Active
- 2018-01-05 CA CA3073555A patent/CA3073555C/en active Active
- 2018-01-05 HU HUE18150455A patent/HUE057332T2/hu unknown
- 2018-01-05 EP EP18700857.8A patent/EP3672623A1/en not_active Withdrawn
- 2018-01-05 EP EP18150455.6A patent/EP3446705B1/en active Active
- 2018-01-05 ES ES18150455T patent/ES2901621T3/es active Active
- 2018-01-05 CN CN201880008885.6A patent/CN110290802A/zh active Pending
- 2018-01-05 WO PCT/EP2018/050273 patent/WO2019037898A1/en not_active Ceased
- 2018-01-05 RU RU2020109130A patent/RU2763934C2/ru active
- 2018-01-05 MX MX2020002053A patent/MX2020002053A/es unknown
- 2018-01-09 KR KR1020180002962A patent/KR102216031B1/ko not_active Expired - Fee Related
- 2018-01-09 US US15/865,870 patent/US11013744B2/en active Active
- 2018-01-09 SG SG10201800195XA patent/SG10201800195XA/en unknown
- 2018-01-09 TW TW107100834A patent/TWI752147B/zh not_active IP Right Cessation
- 2018-01-09 CA CA2991357A patent/CA2991357A1/en not_active Abandoned
- 2018-02-08 JP JP2018021069A patent/JP2019038797A/ja active Pending
-
2021
- 2021-05-24 US US17/329,075 patent/US12527796B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| LT3580220T (lt) | Aminotriazolopiridinai, kaip kinazės inhibitoriai | |
| EP3490564A4 (en) | MACRO CYCLE Kinase Inhibitors | |
| DK3687999T3 (da) | Rapamycinderivater | |
| DK3563512T3 (da) | Dynamisk hemmelighedssystem med tvetydighedsforstærkning | |
| DK3642202T3 (da) | Dihydro-pyrrolo-pyridin-derivater | |
| IL265166B (en) | Anti-influenza virus pyrimidine derivatives | |
| PL3890206T3 (pl) | Transmisja kształtowana wiązką w systemie komórkowym | |
| CL2016002461A1 (es) | Derivados macrocíclicos de pirimidina | |
| DK3253762T3 (da) | 9h-pyrrolo-dipyridinderivater. | |
| DK3302179T3 (da) | Fjeder i lomme | |
| LT3704118T (lt) | Aminoimidazopiridazinai, kaip kinazės inhibitoriai | |
| PL3359543T3 (pl) | Pochodne kukurbiturylu | |
| DK3446706T3 (da) | [6r]-mthf-fler-bolus-indgivelse i 5-fluoruracilbaseret kemoterapi | |
| EP3492057A4 (en) | VOIDABLE ARTICLE | |
| HUE057332T2 (hu) | [6R]-MTHF, egy hatásos folátalternatíva 5-fluoruracil-alapú kemoterápiában | |
| LT3402782T (lt) | 8-amino-2-okso-1,3-diaza-spiro-[4.5]-dekano dariniai | |
| EP3663026A4 (en) | Lathe | |
| EP3377473C0 (en) | BROAD SPECTRUM MACROCYCLIC ANTIBIOTICS | |
| UY4652S (es) | Soporte de auricular | |
| EP3643295A4 (en) | COMPOSITION CONTAINING AN EXTRACT OF CIRSIUM JAPONICUM AS AN ACTIVE PRINCIPLE FOR STIMULATING MELANOGENESIS | |
| EP3377474C0 (en) | BROAD-SPECTRUM MACROCYCLIC ANTIBIOTICS | |
| EP3445347A4 (en) | IMPROVEMENT OF CHEMOTHERAPY | |
| DK3372589T3 (da) | Pyrimidinderivat | |
| EP3346592A4 (en) | Rotating machine | |
| HRP20190328T1 (hr) | Pripravak za topikalnu primjenu u slušnom kanalu |